News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Kythera Biopharmaceuticals Completes Enrollment in Pivotal U.S. and Canadian Phase III Clinical Trials to Evaluate ATX-101 for Reduction of Submental Fat



9/4/2012 10:13:26 AM

LOS ANGELES--(BUSINESS WIRE)--KYTHERA Biopharmaceuticals, Inc. (KYTHERA) today announced the completion of enrollment in two pivotal U.S. and Canadian Phase III clinical trials of ATX-101, a potential first-in-class injectable facial aesthetic drug under clinical investigation for the reduction of submental fat, which commonly presents as an undesirable “double chin.” KYTHERA expects to release top-line results in mid-2013.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES